Results 81 to 90 of about 46,300 (164)

Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches

Journal of Pharmacy & Pharmaceutical Sciences
Excess adiposity can contribute to metabolic complications, such as type 2 diabetes mellitus (T2DM), which poses a significant global health burden.
Arianne Morissette, Erin E. Mulvihill, Erin E. Mulvihill   +2 more
doaj   +1 more source

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice [PDF]

, 2016
Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of
Avogaro, Angelo, Bonora, Enzo, Fadini, GIAN PAOLO, Prato, Stefano Del, Sesti, Giorgio   +4 more
core   +3 more sources

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration

Biomolecules
Glucagon-like peptide-1 (GLP-1)-based drugs have been approved by the United States Food and Drug Administration (FDA) and are widely used to treat type 2 diabetes mellitus (T2DM) and obesity.
Katherine O. Kopp, Yazhou Li, Elliot J. Glotfelty, David Tweedie, Nigel H. Greig   +4 more
doaj   +1 more source

GLP-1 Receptor Agonists and Kidney Protection

Medicina, 2019
Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Diabetic nephropathy (DN) is determined by specific pathological structural and functional alterations of the kidneys in patients with diabetes, and its clinical ...
Eulalia Valentina Greco, Giuseppina Russo, Annalisa Giandalia, Francesca Viazzi, Roberto Pontremoli, Salvatore De Cosmo   +5 more
doaj   +1 more source

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties

Medicina
As an incretin hormone, Glucagon-like peptide-1 (GLP-1) has obvious effects on blood glucose regulation and weight loss. GLP-1 receptor (GLP-1R) agonists are synthetic products that have similar effects to GLP-1 but are less prone to degradation, and ...
Chenqi Lu, Cong Xu, Jun Yang
doaj   +1 more source

The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review

Drug Design, Development and Therapy
Zhao Liu,1 Shanshan Yu,1 Xinyan Jin,1 Luguang Sheng,2 Mai Re YanMu,1 Jie Gao,1 Jun Lu,1 Tao Lei1 1Department of Endocrinology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 2Department of ...
Liu Z, Yu S, Jin X, Sheng L, YanMu MR, Gao J, Lu J, Lei T   +7 more
doaj  

GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats

Endocrine Connections
Objective: Combination therapies with gut hormone analogs represent promising treatment strategies for obesity. This pilot study investigates the therapeutic potential of modulators of the glucagon-like peptide 1 (GLP-1) and neuropeptide Y (NPY) system ...
Marie Oertel, Christian G Ziegler, Michael Kohlhaas, Alexander Nickel, Simon Kloock, Christoph Maack, Vasco Sequeira, Martin Fassnacht, Ulrich Dischinger   +8 more
doaj   +1 more source

Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants

Frontiers in Pharmacology
BackgroundObesity is a chronic inflammatory disease with high morbidity that is decidedly prevalent worldwide and in Saudi Arabia. Glucagon-like peptide 1 receptor agonists (GLP-1 agonists) are broadly used for the management of diabetes and obesity.
Amirah Alhowiti, Hyder Mirghani, Abdulaziz Abdulrahman Qrmli, Amal Abdullah Albalawi, Raneem Abdulrahman Aljohani   +4 more
doaj   +1 more source

The Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS

Quality in Sport
Introduction and aim of study: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting young women. It is diagnosed in individuals who meet 2 of the following 3 criteria: hyperandrogenism, ovarian dysfunction or ...
Aleksandra Jaroń, Agata Wiklińska, Katarzyna Jastrzębska, Maria Witkowska, Joanna Skotnicka, Karolina Błaszczak, Monika Turek, Klara Wojciechowska, Adrian Borkowski, Mateusz Sawicki   +9 more
doaj   +1 more source

The Role of the Dietitian in Incretin-Based Obesity Therapies in Italy: Practical Clinical Challenges, Professional Clarity, and the Sarcopenic Obesity Perspective

Dietetics
Background: Incretin-based therapies, including glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonists, advance obesity treatment by promoting weight loss and lowering the ...
Daniela Ojeda-Mercado, Maurizio Fadda, Benedetta Beltrame, Martina Tosi, Amalia Bruno, Carmen Di Scala, Giancarlo Travaglia, Assunta Vitale, Rita Schiano di Cola, Stefano Boschetti, Federica Pessina, Roberta Jaccheri, Liisa Tolvanen   +12 more
doaj   +1 more source